Tag Archives: SPHS

Sophiris Bio (SPHS) Receives a Buy from Maxim Group

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Sophiris Bio (SPHS – Research Report), with a price target of $6. The company’s shares closed on Tuesday at $2.10, close to its 52-week low

Sophiris Bio (SPHS) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sophiris Bio (NASDAQ: SPHS) today and set a price target of $10. The company’s shares closed yesterday at $2.76. Pantginis said: “Valuation and risks to price target achievement. We reiterate

Maxim Group Maintains Their Buy Rating on Sophiris Bio (SPHS)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Sophiris Bio (NASDAQ: SPHS), with a price target of $8. The company’s shares opened today at $3.04. McCarthy observed: “Sophiris announced that the investigation into

H.C. Wainwright Thinks Sophiris Bio’s Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Sophiris Bio (NASDAQ: SPHS) today and set a price target of $4.30. The company’s shares opened today at $1.97, close to its 52-week low of $1.80. Pantginis wrote: “Valuation and

Maxim Group Keeps a Buy Rating on Sophiris Bio

Maxim Group analyst Jason McCarthy maintained a Buy rating on Sophiris Bio (NASDAQ: SPHS) today and set a price target of $8. The company’s shares opened today at $3.73, close to its 52-week high of $4.05. McCarthy observed: “We note

Maxim Group Believes Sophiris Bio (NASDAQ: SPHS) Still Has Room to Grow

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Sophiris Bio (NASDAQ: SPHS), with a price target of $8. The company’s shares closed yesterday at $3.09, close to its 52-week high of $3.14. McCarthy